Parliament Workbench
Data: Motions & questions to 26 Nov 2026

Written Question · S7W-00710 · Session 7

What action it is taking, following the withdrawal of hydrocortisone sodium phosphate 100mg/1ml solution, to ensure that people with adrena…

Answered Asked by Alex Cole-Hamilton LD Lodged 1 Jun 2026

The question

To ask the Scottish Government what action it is taking, following the withdrawal of hydrocortisone sodium phosphate 100mg/1ml solution, to ensure that people with adrenal insufficiency have access to safe, rapid-use emergency hydrocortisone options, including alternative liquid products, the ACT-O-VIAL system and future prefilled or autoinjector delivery methods.

The answer

Answered by Maree Todd on 16 Jun 2026 · 15 days after it was lodged, on time

The supply of medicines, and the associated legislation, is a matter reserved to the UK Government. The Chief Pharmaceutical Officer for Scotland is a member of the UK Medicines Shortage Response Group (MSRG). Following the discontinuation of hydrocortisone sodium phosphate 100mg/1ml solution, MSRG issued advice to prescribers to switch people to hydrocortisone sodium succinate 100mg powder for injection, where appropriate. People concerned about the additional steps required to prepare an emergency injection when using the above-noted powder formulation may wish to discuss with their clinician whether an alternative unlicensed hydrocortisone product would be appropriate for them. Work with the pharmaceutical industry to identify a longer-term solution continues.

In the Official Report

No contribution in the Official Report cites S7W-00710 by reference.